Mark M. Awad
YOU?
Author Swipe
View article: Supplementary Figure S10 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
Supplementary Figure S10 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC Open
Integrated model for patient stratification and clinical outcome prediction with KRAS G12Ci monotherapy in KRASG12C-mutant NSCLC.
View article: Supplementary Figure S8 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
Supplementary Figure S8 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC Open
A) Survival outcomes in patients with additional RAS co-alterations (KRAS amplification, other KRAS, NRAS and/or HRAS somatic mutations) in the KSCWT population; B) outcomes according to AKT1/PIK3CA/MTOR/TSC1/2/PTEN co-mutation status for …
View article: Supplementary Table S5 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
Supplementary Table S5 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC Open
Multivariable analysis - overall survival
View article: Supplementary Table S4 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
Supplementary Table S4 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC Open
Multivariable analysis - progression-free survival
View article: Supplementary Figure S4 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
Supplementary Figure S4 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC Open
Clinical outcomes with KRAS G12Ci therapy according to co-mutation status for A) KEAP1, B) SMARCA4, and C) CDKN2A in patients previously treated with immune checkpoint inhibitors.
View article: Supplementary Figure S1 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
Supplementary Figure S1 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC Open
Clinical outcomes in Cohorts A (left) and B (right). A) progression-free survival; B) overall survival.
View article: Supplementary Figure S9 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
Supplementary Figure S9 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC Open
A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NG…
View article: Supplementary Table S2 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
Supplementary Table S2 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC Open
Baseline Patient Characteristics – Cohort A
View article: Supplementary Table S3 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
Supplementary Table S3 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC Open
Baseline Patient Characteristics – Cohort B
View article: Supplementary Figure S2 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
Supplementary Figure S2 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC Open
A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease and without untreated brain metastases; B) Survival outcomes in patients with treated or untreated brain me…
View article: Supplementary Figure S3 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
Supplementary Figure S3 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC Open
Survival outcomes according to KEAP1 (A), SMARCA4 (B), and CDKN2A (C) co-mutation status in Cohorts A and B.
View article: Supplementary Figure S5 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
Supplementary Figure S5 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC Open
Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) Cohort B; C) further subclassifying KEAP1MUT tumors according to STK11 mutation status; D) PFS and OS according to STK11 co-mutation status in KSCWT tumors …
View article: Supplementary Figure S6 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
Supplementary Figure S6 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC Open
Progression-free survival (left) and overall survival (right) according to TP53 co-mutation status in A) overall cohort, B) cohort A, and C) cohort B.
View article: Supplementary Figure S7 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
Supplementary Figure S7 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC Open
Progression-free survival (left) and overall survival (right) according to co-mutation status for (A) CHEK2 and (B) ATRX in the overall mutation-evaluable population.
View article: Supplementary Table S6 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
Supplementary Table S6 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC Open
List of major molecular profiling platforms included in the cohort
View article: Supplementary Table S1 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
Supplementary Table S1 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC Open
Baseline Patient Characteristics – Overall Cohort
View article: Supplementary Figure 21 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 21 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 21. (A) Intratumoral, (B) tumor-stroma interface, and (C) total CD8+ PD1+ T cells in ATMMUT and ATMWT NSCLCs. (D) Intratumoral, (E) tumor-stroma interface, and (F) total FOXP3+ immune cells in ATMMUT and ATMWT NSCLCs.
View article: Supplementary Figure S6 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure S6 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer Open
Univariable analyses of association of clinical characteristics with long-term response (LTR) compared to short-term response (STR), non-LTR, and progressive disease (PD).
View article: Supplementary Table S7 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i>-Mutant and <i>RET</i> Fusion-Positive Lung Cancers
Supplementary Table S7 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i>-Mutant and <i>RET</i> Fusion-Positive Lung Cancers Open
Response to combination therapy
View article: Supplementary Table 4 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Table 4 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Table 4. Baseline clinicopathologic features of patients with ATM mutated NSCLC according ATM protein expression by immunohistochemistry.
View article: Supplementary Figure S11 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure S11 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer Open
Genomic features of patients with long-term response (LTR) compared to short term response (STR), non-LTR, and progressive disease (PD) among patients with TMB z-score < 0.
View article: Supplementary Table S6 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i>-Mutant and <i>RET</i> Fusion-Positive Lung Cancers
Supplementary Table S6 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i>-Mutant and <i>RET</i> Fusion-Positive Lung Cancers Open
Dose discontinuation
View article: Supplementary Table S4 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i>-Mutant and <i>RET</i> Fusion-Positive Lung Cancers
Supplementary Table S4 from Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i>-Mutant and <i>RET</i> Fusion-Positive Lung Cancers Open
Adverse events observed with combination therapy
View article: Supplementary Figure 14 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 14 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 14. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 immune checkpoint blockade monotherapy among patients with advanced/metastatic PD-L1 negative (<1%) NSCLC, according t…
View article: Supplementary Figure 18 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 18 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 18. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 immune checkpoint blockade monotherapy among patients with ATMMUT NSCLC, according to STK11 mutation. (D) Objective re…
View article: Supplementary Figure 10 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 10 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 10. (A) Progression-free and (B) overall survival among all patients with stage III NSCLC according to ATM mutation status. (C) Progression-free and (D) overall survival among patients with stage III NSCLC who received…
View article: Supplementary Table S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Table S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer Open
List of PD-L1 antibodies used at each site and in the combined cohort.
View article: Supplementary Table S2 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Table S2 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer Open
List of 301 genes included in all versions of MSK-IMPACT and DFCI OncoPanel NGS platforms used for all analyses.
View article: Supplementary Figure 4. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
Supplementary Figure 4. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer Open
Supplementary Figure 4. (A) Volcano plot showing gene mutations significantly enriched among NSCLCs harboring ATM missense mutations that were predicted to benign in silico versus NSCLCs without any ATM mutation. (B) Volcano plot showing g…
View article: Supplementary Table S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Table S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer Open
Frequencies of alterations in individual genes among non-squamous patient groups stratified by TMB z-score.